BioDelivery Sciences International (NSDQ:BDSI) said today that it reacquired the license to the Belbuca (buprenorphine) buccal film from Endo Pharmaceuticals. Malvern, Penn-based Endo Pharmaceuticals licensed the worldwide manufacturing and marketing rights to the opioid patch from BioDelivery in 2012.
Belbuca, a once-daily opioid, is indicated for the management of severe pain. The small, peppermint-flavored film works by sticking to the cheek and dissolving within 30 minutes. Projections show that Belbuca gross sales will exceed $27 million, according to Raleigh, N.C.-based BioDelivery.
Get the full story at our sister site, Drug Delivery Business News.
The post BioDelivery reacquires license to buprenorphine film appeared first on MassDevice.
from MassDevice http://ift.tt/2hoYBA2
Cap comentari:
Publica un comentari a l'entrada